Morgan Stanley Lowers Y-mAbs Therapeutics NASDAQ:YMAB to Underweight
The New York, NY-based company was founded in 2015 and plans to list on the Nasdaq under the symbol YMAB. BofA Merrill Lynch and Cowen are the joint bookrunners on the deal. © 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Y-mabs Therapeutics earns the No. 120 rank among…